Atzout mono-anti-nab-purple alcohol combination approved for immunotherapy for triple-negative breast cancer!

4 June 2020 /BiovalleyBIOON / - The National Institute for Health and Clinical Excellence (NICE) has approved a new immunotherapy to treat adults in the UK with awith triple-negativebreast cancerUsing a combination of Atezolizumab (Tecentriq) and abraxane, Tecentriq is the first immunotherapy of its kind to be used for this type of cancerThe final decision was in response to a new data analysis and revised price submission from the company that developed atezolizumab, which was originally rejected by NICE in October last yearEmlyn Samuel, cancer research UK's head of policy development, said the decision was "fantastic news."Samuel added: "For the first time, some people with this type of malignant breast cancer can receive immunotherapy"
new treatment regimen
Atezolizumab's combination chemotherapy drug na
b-sequoia alcohol will be a new option for adult patients with triple-negative breast cancer who have spread to other parts of the body while surgery has been ruled outPhoto: LRI EM Unit Breast cancer cell
This method is only available to patients whotumors tested positive for PD-L1 and have not undergone chemotherapy after the cancer cells have spread Atezolizumab is an immunotherapy called checkpoint inhibitors that increase the chances that immune cells will kill tumor cells by preventing PD-L1 from interacting with immune cells In the UK, about 2,000 people have triple-negative breast cancer, of whom about 600 are eligible for immunotherapy This type of breast cancer usually occurs in younger patients and may be more aggressive than other types of breast cancer Life-extending treatment
clinical trials evidence that atezolizumab combined nab-yew alcohol can extend the patient's progressionless survival In clinical trials , patients treated with immunotherapy had a progression survival of 7.5 months, while patients treated with placebo plus nab-yew alcohol had a non-progressive survival period of 5 months The overall survival rate also rose from 15.5 months to 25 months "This has real benefits for patients -- clinical trials evidence that this combination of drugs can give patients more time and may help them live longer," Samuel said Professor Peter Johnson, clinical director of cancer at NHS England, said: "We are delighted to have reached an agreement with NICE to support NICE's recommendation to atezolizumab, which will help hundreds of breast cancer patients and their families - meaning patients with triple-negative breast cancer have better treatment options "
new hope
further data analysis and lower prices (agreed by the NHS and the manufacturers of atezolizumab) have allowed NICE to offer this treatment in the NHS after the initial decision last October not to recommend the combination During the review, the treatment was found to meet the NICE condition and is considered a life-extending treatment, giving NICE extra flexibility in deciding whether to approve the cost-benefit criteria used in a new treatment Samuel said: "Cancer does not stop as a pandemic, patients and clinicians have told NICE that triple-negative breast cancer does require new treatments, so we are pleased that today's decision will give new hope to some people affected by the disease "
NICE's decision is usually adopted in Wales, Northern Ireland and England, so it could affect patients in those three countries Scotland, meanwhile, has an independent procedure to examine which drugs should be included in the NHS (BioValleyBioon.com) References: 's Immunotherapy for triple-breasted cancer approved for NHS in England by Cancer Research UK Atezolizumab with nab-paclit forAxeling PD L1-triple, breast-inf cancer (ID1522) .. id-ta10433/documents
Peter Schmid et al.
Atezolizumab and Nab-Paclitaxel in Advanced Negative-Breast Cancer , New England Journal of Medicine (2018) DOI: 10.1056/NEJMoa1809615